Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients

(2010) D R J Kuypers   CLINICAL PHARMACOLOGY & THERAPEUTICS

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients

(2008) Xiao-yan Qiu et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients

(2008) Dennis A. Hesselink et al.   Pharmacogenetics and Genomics

CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients

(2008) Séverine Crettol et al.   THERAPEUTIC DRUG MONITORING

Significant Impact of Gene Polymorphisms on Tacrolimus But Not Cyclosporine Dosing in Asian Renal Transplant Recipients

(2008) P.T. Loh et al.   TRANSPLANTATION PROCEEDINGS